Breaking News, Financial News

Financial Report: Roche 1Q

Pharmaceuticals Division sales were down 2% in the quarter.

Roche 1Q

1Q Revenues: $12.4 billion (-9%)

Comments: Pharmaceuticals Division sales were down 2% in the quarter. Avastin sales were impacted by regulatory and reimbursement uncertainty in the U.S. for the metastatic breast cancer indication. Lucentis, MabThera/Rituxan, Herceptin, Actemra/RoActemra, Activase/TNKase, Tarceva and Xeloda, performed well in the quarter. The exchange rate impacted sales by 1.1 billion Swiss francs or 9%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters